Roivant Sciences Ltd. (ROIV) Stock Analysis

Q: What is the ROIV stock price target?

Take-profit $31.03 (+9.4% upside). Prior stop was $26.55.

Q: Is ROIV overvalued or undervalued?

Roivant Sciences Ltd. trades at a P/E of N/A (forward -23.7). TrendMatrix value score: 6.0/10. Overall verdict: Sell.

Q: What do analysts say about ROIV?

19 analysts cover ROIV with a consensus score of 4.3/5. Average price target: $36.

Range Bound setup

SellVALUE-TRAP 2/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Sell if holding. Engine safety override at $28.34: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Below-average business quality; Negative price momentum.

$28.34+9.4% A.UpsideScore 4.4/10#135 of 158 Biotechnology

Stop $26.55Target $31.03(analyst − 13%)A.R:R 1.5:1

Analyst target$35.67+25.9%12 analysts

$31.03our TP

$28.34price

$35.67mean

$41

Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 28d clear, semi cycle peak clear). Fails on weak momentum. Suitability: moderate.

Thesis

Rewards

No bull case signals

Risks

Quality below floor (1.5 < 4.0)

Value-trap signals (2/5): Material insider selling (17 sells, 0.06% of cap), Negative free cash flow

Key Metrics

P/E (TTM)—

P/E (Fwd)-23.7

Mkt Cap$19.7B

EV/EBITDA-12.6

Profit Mgn0.0%

ROE-19.1%

Rev Growth-77.8%

Beta1.21

DividendNone

Rating analysts19

Quality Signals

Piotroski F2/9

Options Flow

P/C0.30bullish

IV52%elevated

Max Pain$10-64.7% vs spot

Concentration Risks(10-K Item 1A)

MEDIUMpipelinesingle or limited number of the Vants
10-K Item 1A: 'a single or limited number of the Vants may, now or in the future, comprise a large proportion of our value'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value6.015%0.90

Quality1.515%0.22

Growth5.015%0.75

Momentum2.710%0.27

Sentiment7.510%0.75

Insider Activity3.010%0.30

Peer Rank4.210%0.42

Technical Setup6.15%0.30

Risk Profile5.65%0.28

Catalyst3.65%0.18

Overall (Σ contributions)4.38

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

2.2

Current Ratio

5.0

Moat

5.0

Cash-burning: FCF -2512% of revenueNo competitive moatWeak Piotroski F-Score: 2/9Quality concerns

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume

0.0

Macd

0.8

Obv

1.0

Rsi

5.5

Ma Position

6.0

Volume distribution (falling OBV)Above 200-day MA

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg

1.2

Earnings History

3.3

Erm

5.0

Earnings Timing

5.0

Earnings concerns: 2B/2M

GatesMomentum 2.7<4.5A.R:R 1.5 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 28d clearSEMI CYCLE PEAK CLEARRange BoundSuitability: Moderate

RSI

51 · Neutral

↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $26.62Resistance $30.18

Price Targets

$27

$31

A.Upside+9.5%

A.R:R1.5:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.5 < 4.0)

! Value-trap signals (2/5): Material insider selling (17 sells, 0.06% of cap), Negative free cash flow

! Momentum score 2.7/10 — below 4.5 minimum

Earnings

2/4 beats

Next Earnings2026-05-28 (28d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is ROIV stock a buy right now?

Sell if holding. Engine safety override at $28.34: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 51 mid-range, Bollinger mid-band. Prior stop was $26.55. Score 4.4/10, moderate confidence.

What is the ROIV stock price target?

Take-profit target: $31.03 (+9.4% upside). Prior stop was $26.55. Stop-loss: $26.55.

What are the risks of investing in ROIV?

Quality below floor (1.5 < 4.0); Value-trap signals (2/5): Material insider selling (17 sells, 0.06% of cap), Negative free cash flow.

Is ROIV overvalued or undervalued?

Roivant Sciences Ltd. trades at a P/E of N/A (forward -23.7). TrendMatrix value score: 6.0/10. Verdict: Sell.

What do analysts say about ROIV?

19 analysts cover ROIV with a consensus score of 4.3/5. Average price target: $36.

What does Roivant Sciences Ltd. do?Roivant Sciences is a clinical-stage biopharmaceutical company developing therapies through nimble Vant subsidiaries,...

Roivant Sciences is a clinical-stage biopharmaceutical company developing therapies through nimble Vant subsidiaries, with a pipeline focused on autoimmune diseases including brepocitinib (TYK2/JAK1, Phase 3), IMVT-1402 (FcRn, Phase 2/3 via Immunovant), batoclimab (FcRn, Phase 3 in thyroid eye disease), and mosliciguat (Phase 2 in pulmonary hypertension). Following the October 2024 divestiture of Dermavant to Organon, Roivant has no commercial products; cash was approximately $4.9 billion as of March 2025. A $1.5 billion share repurchase program was authorized, with approximately $1.3 billion